Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 48-57

  Zhang, Linlin ^a,b   Li, Lei ^a,b   Jiao, Min ^a   Wu, Dapeng ^a   Wu, Kaijie ^a   Li, Xiang ^a   Zhu, Guodong ^a   Yang, Lin ^a   Wang, Xinyang ^a   Hsieh, Jer Tsong ^c   He, Dalin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer stem cell; Genistein; Prostate cancer; Tumorsphere cell

Indexed keywords

DOCETAXEL; GENISTEIN; HERMES ANTIGEN; MESSENGER RNA; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION REGULATION; GLI1 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GENE;

ANIMALS; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; GENISTEIN; HEDGEHOG PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

ERINACEIDAE; GLYCINE MAX;

EID: 84861807248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.037     Document Type: Article

References (41)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60(2010):277-300.
2. Schroder F.H. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur. Urol. 2008, 53:1129-1137.
3. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1665-1671.
4. Dick J.E. Acute myeloid leukemia stem cells. Ann. NY Acad. Sci. 2005, 1044:1-5.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
6. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
7. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
8. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
9. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
10. Pietras A. Cancer stem cells in tumor heterogeneity. Adv. Cancer Res. 2011, 112:255-281.
11. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68:3243-3250.
12. Hambardzumyan D., Squatrito M., Holland E.C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10:454-456.
13. Rich J.N., Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355.
14. Zhang L., Jiao M., Li L., Wu D., Wu K., Li X., Zhu G., Dang Q., Wang X., Hsieh J.T., He D. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 2012, 138:675-686.
15. Li H., Tang D.G. Prostate cancer stem cells and their potential roles in metastasis. J. Surg. Oncol. 2011, 103:558-562.
16. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 2008, 26:2862-2870.
17. Shenouda N.S., Zhou C., Browning J.D., Ansell P.J., Sakla M.S., Lubahn D.B., Macdonald R.S. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr. Cancer 2004, 49:200-208.
18. Luk S.U., Yap W.N., Chiu Y.T., Lee D.T., Ma S., Lee T.K., Vasireddy R.S., Wong Y.C., Ching Y.P., Nelson C., Yap Y.L., Ling M.T. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 2011, 128:2182-2191.
19. Luk S.U., Lee T.K., Liu J., Lee D.T., Chiu Y.T., Ma S., Ng I.O., Wong Y.C., Chan F.L., Ling M.T. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS ONE 2011, 6:e19804.
20. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53:160-170.
21. Hewitt A.L., Singletary K.W. Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett. 2003, 192:133-143.
22. Taylor C.K., Levy R.M., Elliott J.C., Burnett B.P. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr. Rev. 2009, 67:398-415.
23. Shimazu T., Inoue M., Sasazuki S., Iwasaki M., Sawada N., Yamaji T., Tsugane S. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am. J. Clin. Nutr. 2010, 91:722-728.
24. Franke A.A., Ashburn L.A., Kakazu K., Suzuki S., Wilkens L.R., Halm B.M. Apparent bioavailability of isoflavones after intake of liquid and solid soya foods. Br. J. Nutr. 2009, 102:1203-1210.
25. Zhang L.L., Li L., Wu D.P., Fan J.H., Li X., Wu K.J., Wang X.Y., He D.L. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol. Sin. 2008, 29:1060-1068.
26. Xie D., Gore C., Liu J., Pong R.C., Mason R., Hao G., Long M., Kabbani W., Yu L., Zhang H., Chen H., Sun X., Boothman D.A., Min W., Hsieh J.T. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc. Natl. Acad. Sci. USA 2010, 107:2485-2490.
27. Li H., Jiang M., Honorio S., Patrawala L., Jeter C.R., Calhoun-Davis T., Hayward S.W., Tang D.G. Methodologies in assaying prostate cancer stem cells. Methods Mol. Biol. 2009, 568:85-138.
28. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
29. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
30. Zhong Y., Guan K., Guo S., Zhou C., Wang D., Ma W., Zhang Y., Li C., Zhang S. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett. 2010, 299:150-160.
31. Gasparini P., Bertolini G., Binda M., Magnifico A., Albano L., Tortoreto M., Pratesi G., Facchinetti F., Abolafio G., Roz L., Tagliabue E., Daidone M.G., Sozzi G. Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Lett. 2010, 296:206-215.
32. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G., Reddy V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106:268-273.
33. Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., MacDonald R.S., Besch-Williford C.L., Lubahn D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010, 70:3382-3390.
34. Song Z., Yue W., Wei B., Wang N., Li T., Guan L., Shi S., Zeng Q., Pei X., Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS ONE 2011, 6:e17687.
35. Wang X., Venugopal C., Manoranjan B., McFarlane N., O'Farrell E., Nolte S., Gunnarsson T., Hollenberg R., Kwiecien J., Northcott P., Taylor M.D., Hawkins C., Singh S.K. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012, 31:187-199.
36. Merchant A.A., Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
37. Olsson E., Honeth G., Bendahl P.O., Saal L.H., Gruvberger-Saal S., Ringner M., Vallon-Christersson J., Jonsson G., Holm K., Lovgren K., Ferno M., Grabau D., Borg A., Hegardt C. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011, 11:418.
38. Su Y.J., Lai H.M., Chang Y.W., Chen G.Y., Lee J.L. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 2011, 30:3186-3199.
39. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J.G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
40. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67:6796-6805.
41. Marhaba R., Klingbeil P., Nuebel T., Nazarenko I., Buechler M.W., Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr. Mol. Med. 2008, 8:784-804.